electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, has announced it completed its Series B financing that has brought in just over $70 million of capital to the company.
Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, announced the completion of a $49.5 million Series A financing to further build its technology platform and advance its lead programs toward clinical development.
Exonics Therapeutics closed on a $40 million Series A financing. It was led by The Column Group.
In a report by Gallup Pakistan short roundup of health infrastructure in Pakistan 2000-2015 based on Pakistan Economic Survey 2015-2016, it is mentioned that “Pakistan was unable to meet its Millennium Development Goals (MDGs) on health and ranks 149 in 188 countries in the first global assessment of countries.
Infant deaths from critical congenital heart disease (CCHD) declined by 33.4 percent in eight states that mandated pulse oximetry screening for newborns, according to a study published online Dec. 5 in JAMA.
Neon Therapeutics, a clinical-stage immuno-oncology company developing neoantigen therapies, today announced the successful completion of an additional $36 million extension to its Series B financing which, combined with $70 million announced in January 2017, brings the total raised during this Series B crossover round to $106 million.
A reported Series E round for HeartFlow, estimated at $150 million, would value the company at more than $1 billion, vaulting it into unicorn territory.
Tokyo-based Astellas Pharma is buying Cambridge, Mass.-based Mitobridge for a total of $390 million. Astellas is pulling the trigger on an acquisition option from a partnership deal the two companies formed in 2013. Under that deal, the two companies collaborated on discovering and developing drugs that target mitochondrial function. The most advanced program from the collaboration is MA-0211, which is presently in Phase I clinical trials for Duchenne muscular dystrophy (DMD). Astellas is an equity investor in Mitobridge already, and is paying $165.5 million in cash in addition to the $60 million in equity it already owns. There is also an additional $225 million in potential milestone payments. John Carroll, with Endpoints News, writes, “For years now, Salk’s Ron Evans—a celebrated serial entrepreneur in scientific circles—has been concentrating on the potential of a new pathway for turning your average couch potato rodent into Mighty Mouse—without exercise…. A couple of ...
For decades now, investigators have been drawn to HIV vaccine research — a Holy Grail in anti-viral research that would have an enormous impact in a world that still sees two million new infections every year.
Monitoring disease activity in individuals with multiple sclerosis, either to predict flare-ups or to check treatment response, might be done with a simple blood test that measures levels of a nerve protein, according to a new study from Norway.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.